Lung Cancer Biopsy Guidance

About Sensome

Sensome is a Paris-based, private medical device innovator founded in 2015, operating in the cardiovascular and interventional medicine sectors. The company has developed a proprietary platform that miniaturizes tissue-sensing via bio-impedance into microchips, which can be integrated into standard minimally invasive devices to provide real-time tissue characterization. Its lead product, the Clotild® Smart Guidewire System for acute ischemic stroke, is in the regulatory stage targeting EU, US, and Japanese markets, with additional clinical-stage programs in lung cancer biopsy and peripheral vascular intervention. Sensome represents a novel approach to data-driven interventional care, backed by strategic manufacturing partners like Asahi Intecc and a consortium of investors.

Therapeutic Areas